Клинический случай применения карипразина при терапевтически резистентной простой шизофрении
https://doi.org/10.31363/2313-7053-2022-4-101-106
Аннотация
Рассмотрен клинический случай применения карипразина у пациентки с терапевтически резистентной простой шизофренией. Представлены дебют и развитие расстройства, фармакологический анамнез. Проанализированы клинические и фармакологические аспекты обоснования выбора карипразина в качестве эффективного и безопасного препарата для лечения шизофрении с преобладающими негативными симптомами.
Ключевые слова
Об авторе
Р. Ф. Насырова
Национальный медицинский исследовательский центр психиатрии и неврологии им. В. М. Бехтерева; Санкт-Петербургская городская психиатрическая больница № 1 им. П. П. Кащенко
Россия
Россия
Регина Фаритовна Насырова, д. м. н., гл. н. с., консультант
Санкт-Петербург
188357
ул. Меньковская, д. 10
Ленинградская обл.
Гатчинский р-н
с. Никольское
Список литературы
1. Calabrese F., Tarazi F. I., Racagni G., Riva M A. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr. 2020; 25 (3): 343–351. doi: 10.1017/S109285291900083X.
2. Cerveri G., Gesi C., Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019; 15: 1525–1535. doi: 10.2147/NDT.S201726
3. Fagiolini A., Alcalá J., Aubel T., et al. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an international panel. Ann Gen Psychiatry. 2020; 19: 55. doi: 10.1186/s12991-020-00305-3.
4. Garcia S., Martinez-Cengotitabengoa M., Lopez-Zurbano S., et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016; 36 (4): 355–371. doi: 10.1097/JCP.0000000000000523
5. Girgis R. R., Slifstein M., D’Souza D., et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11) C]-(+)-PHNO. Psychopharmacology. 2016; 233 (19–20): 3503–3512. doi: 10.1007/s00213-016-4382-y.
6. Haddad P. M., Correll C. U. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018; 8 (11): 303–318. doi: 10.1177/2045125318781475.
7. Howes O. D., Thase M. E., Pillinger T. Treatment resistance in psychiatry: State of the art and new directions. Mol. Psychiatry.2022; 27: 58–72.
8. Huhn M., Nikolakopoulou A., Schneider-Thoma J., et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394 (10202): 939–951. doi: 10.1016/S0140-6736(19)31135-3
9. Hunter R., Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry. 2012; 27 (6): 432–436. doi: 10.1016/j.eurpsy.2011.02.015.
10. Insel TR. Rethinking schizophrenia. Nature. 2010; 468 (7321): 187–193. doi: 10.1038/nature09552.
11. Kanchanatawan B., Thika S., Anderson G., Galecki P., Maes M. Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 80 (Pt C): 168–176. doi: 10.1016/j.pnpbp.2017.06.031.
12. Kane J. M., Agid O., Baldwin M. L., Howes O., Lindenmayer J. P., Marder S., Olfson M., Potkin S. G., Correll C. U. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J. Clin. Psychiatry. 2019; 80: 2783.
13. Keks N., Hope J., Schwartz D., et al. Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020; 34 (5): 473–507. doi: 10.1007/s40263-020-00718-4.
14. Laursen T. M. Life expectancy among personswith schizophrenia or bipolar affective disorder. Schizophr. 2011; 131: 101–104.
15. Laszlovszky I., Barabássy Á., Németh G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety Adv Ther. 2021; 38 (7): 3652–3673. doi: 10.1007/s12325-021-01797-5.
16. Owen M. J., Sawa A., Mortensen P. B. Schizophrenia. Lancet. 2016; 388 (10039): 86–97. doi: 10.1016/S0140-6736(15)01121-6.
17. Perälä J., Suvisaari J., Saarni S. I., et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007; 64 (1): 19–28. doi: 10.1001/archpsyc.64.1.19.
18. Pillinger T., McCutcheon R. A., Vano L., et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020; 7 (1): 64–77. doi: 10.1016/S2215-0366(19)30416-X.
19. Rabinowitz J., Berardo C. G., Bugarski-Kirola D., Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr. 2013; 150 (2–3): 339–342. doi: 10.1016/j.schres.2013.07.014.
20. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch. Gen. Psychiatry. 2007; 64: 1123–1131.
21. Suttajit S., Pilakanta S. Predictors of quality of life among individuals with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 1371–1379. doi: 10.2147/NDT.S81024.
22. Vita A., Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 2018; 31 (3): 246–255. doi: 10.1097/YCO.0000000000000407
Рецензия
Для цитирования:
Насырова Р.Ф. Клинический случай применения карипразина при терапевтически резистентной простой шизофрении. Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева. 2022;56(4):101-106. https://doi.org/10.31363/2313-7053-2022-4-101-106
For citation:
Nasyrova R.F. Clinical case of the use of cariprazine in treatment-resistant simple schizophrenia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2022;56(4):101-106. (In Russ.) https://doi.org/10.31363/2313-7053-2022-4-101-106
Просмотров:
596
Послать статью по эл. почте 